A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- AmpliMed Corporation
- Registration Number
- NCT00697060
- Locations
- ๐บ๐ธ
USC Norris Cotton Cancer Center, Los Angeles, California, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธMary Crowley Research Center, Dallas, Texas, United States
A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- AmpliMed Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT00637247
- Locations
- ๐บ๐ธ
Cancer Center of North Carolina- US Oncology, Raleigh, North Carolina, United States
๐บ๐ธCentral Indiana Cancer Centers- US Oncology, Indianapolis, Indiana, United States
๐บ๐ธNorthern Indiana Cancer Research Consortium, South Bend, Indiana, United States
Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients
- Conditions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2009-08-11
- Lead Sponsor
- AmpliMed Corporation
- Registration Number
- NCT00327249
- Locations
- ๐บ๐ธ
Investigational Site 025, Little Rock, Arkansas, United States
๐บ๐ธInvestigational Site 008, Houston, Texas, United States
Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma
- Conditions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- AmpliMed Corporation
- Target Recruit Count
- 105
- Registration Number
- NCT00327327
- Locations
- ๐บ๐ธ
US Oncology Albany, New York Oncology, Albany, New York, United States
๐บ๐ธUS Oncology Orlando, Cancer Centers of FL, Ocoee, Florida, United States
๐บ๐ธUS Oncology Kettering, Kettering, Ohio, United States
Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- AmpliMed Corporation
- Target Recruit Count
- 68
- Registration Number
- NCT00327600
- Locations
- ๐บ๐ธ
University of CO Anschutz Cancer Pavilion, Aurora, Colorado, United States
๐บ๐ธInvestigational Site 012, Salt Lake City, Utah, United States
๐บ๐ธUS Oncology Greenville, Cancer Centers of the Carolinas, Greenville, South Carolina, United States
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- AmpliMed Corporation
- Target Recruit Count
- 34
- Registration Number
- NCT00327288
- Locations
- ๐บ๐ธ
Investigational Site 008, Houston, Texas, United States
Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2008-03-14
- Lead Sponsor
- AmpliMed Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT00327223
- Locations
- ๐บ๐ธ
US Oncology, Tyler Cancer Center, Tyler, Texas, United States
๐บ๐ธUS Oncology Indiana, Indianapolis, Indiana, United States
๐บ๐ธUS Oncology Albany, New York Oncology, Albany, New York, United States